BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37731937)

  • 1. The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis.
    van Hylckama Vlieg MAM; Nasserinejad K; Visser C; Bramer WM; Ashrani AA; Bosson JL; Crusan DJ; D'Alessio A; Fluharty ME; Ģībietis V; Hansson PO; Hara N; Jara-Palomares L; Kraaijpoel N; Mahé I; Marshall A; Ogino Y; Otero R; Versmissen J; Klok FA; Kruip MJHA; van der Rijt CCD; Geijteman ECT
    EClinicalMedicine; 2023 Oct; 64():102194. PubMed ID: 37731937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
    Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
    BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.
    Khan F; Tritschler T; Kimpton M; Wells PS; Kearon C; Weitz JI; Büller HR; Raskob GE; Ageno W; Couturaud F; Prandoni P; Palareti G; Legnani C; Kyrle PA; Eichinger S; Eischer L; Becattini C; Agnelli G; Vedovati MC; Geersing GJ; Takada T; Cosmi B; Aujesky D; Marconi L; Palla A; Siragusa S; Bradbury CA; Parpia S; Mallick R; Lensing AWA; Gebel M; Grosso MA; Shi M; Thavorn K; Hutton B; Le Gal G; Rodger M; Fergusson D
    J Thromb Haemost; 2021 Nov; 19(11):2801-2813. PubMed ID: 34379859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis.
    Khan F; Rahman A; Carrier M; Kearon C; Schulman S; Couturaud F; Prandoni P; Eichinger S; Becattini C; Agnelli G; Büller HR; Brighton TA; Palareti G; Pinede L; Sabri E; Hutton B; Wells GA; Rodger MA;
    BMJ Open; 2017 Sep; 7(9):16950. PubMed ID: 28939565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.
    Barca-Hernando M; Lopez-Ruz S; Marin-Romero S; Garcia-Garcia V; Elias-Hernandez T; Otero-Candelera R; Carrier M; Jara-Palomares L
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100115. PubMed ID: 37063761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
    Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
    Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol.
    Khan F; Kimpton M; Tritschler T; Le Gal G; Hutton B; Fergusson DA; Rodger MA
    Syst Rev; 2019 Oct; 8(1):245. PubMed ID: 31661033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review.
    van der Wall SJ; van der Pol LM; Ende-Verhaar YM; Cannegieter SC; Schulman S; Prandoni P; Rodger M; Huisman MV; Klok FA
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30487292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer.
    van der Hulle T; den Exter PL; van den Hoven P; van der Hoeven JJ; van der Meer FJ; Eikenboom J; Huisman MV; Klok FA
    Chest; 2016 May; 149(5):1245-51. PubMed ID: 26836911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
    Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
    PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
    Carrier M; Le Gal G; Wells PS; Rodger MA
    Ann Intern Med; 2010 May; 152(9):578-89. PubMed ID: 20439576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet agents for the treatment of deep venous thrombosis.
    Flumignan CD; Nakano LC; Baptista-Silva JC; Flumignan RL
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012369. PubMed ID: 35876829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study.
    Martinez C; Katholing A; Folkerts K; Cohen AT
    J Thromb Haemost; 2016 Jul; 14(7):1374-83. PubMed ID: 27079164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis.
    Wang TF; Carrier M; Carney BJ; Kimpton M; Delluc A
    Thromb Res; 2023 Jul; 227():8-16. PubMed ID: 37196605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.